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Excessive tumor necrosis factor (TNF) is known to cause significant
pathology. Paradoxically, deficiency in TNF (TNF−/−) also caused
substantial pathology during respiratory ectromelia virus (ECTV)
infection, a surrogate model for smallpox. TNF−/− mice succumbed
to fulminant disease whereas wild-type mice, and those engineered
to express only transmembrane TNF (mTNF), fully recovered. TNF
deficiency did not affect viral load or leukocyte recruitment but
caused severe lung pathology and excessive production of the cyto-
kines interleukin (IL)-6, IL-10, transforming growth factor beta (TGF-
β), and interferon gamma (IFN-γ). Short-term blockade of these cyto-
kines significantly reduced lung pathology in TNF−/− mice concomi-
tant with induction of protein inhibitor of activated STAT3 (PIAS3)
and/or suppressor of cytokine signaling 3 (SOCS3), factors that inhibit
STAT3 activation. Consequently, inhibition of STAT3 activation with
an inhibitor reduced lung pathology. Long-term neutralization of IL-6
or TGF-β protected TNF−/− mice from an otherwise lethal infection.
Thus, mTNF alone is necessary and sufficient to regulate lung inflam-
mation but it has no direct antiviral activity against ECTV. The data
indicate that targeting specific cytokines or cytokine-signaling path-
ways to reduce or ameliorate lung inflammation during respiratory
viral infections is possible but that the timing and duration of the
interventive measure are critical.
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Tumor necrosis factor (TNF) plays essential roles in normalphysiology (1), maintenance of immune homeostasis, acute
inflammation, and antimicrobial defense (2–8). It has also been
implicated in many of the detrimental effects of chronic in-
flammation in autoimmune conditions (9) and during infection
(10, 11). The antimicrobial property of TNF has been under-
scored in patients receiving anti-TNF therapy to treat TNF-
mediated inflammatory diseases, which has been shown to re-
sult in reactivation of some bacterial, parasitic, and fungal and a
limited number of viral infections (6, 7, 12, 13).
TNF is produced following activation of the nuclear factor
kappa B (NF-κB) inflammatory pathway, often in response to
stress or infection. It is expressed as a transmembrane protein
(mTNF), which is then cleaved by metalloproteinases to produce
the secreted form, sTNF (14, 15). Both forms of TNF can mediate
effector functions, but the relative contribution of each during viral
infection is unknown. TNF is known to contribute to an exagger-
ated immune response leading to host tissue destruction and im-
munopathology during some viral infections (16).
Some members of the Orthopoxvirus (OPXV) genus, like
variola virus (agent of smallpox), monkeypox virus, cowpox virus,
and ectromelia virus (ECTV) encode several host response
modifiers including TNF receptor (TNFR) homologs, suggesting
an important immunoprotective role for TNF (17–20). ECTV is
a mouse pathogen that causes mousepox, a disease very similar
to smallpox, and is widely used to investigate the pathogenesis of
OPXV infections. At least two lines of evidence indicate that
TNF plays a crucial role in protection and recovery of mice from
OPXV infections. First, resistance to ECTV infection in mice is
strongly associated with TNF production (21). Resistant mice
like the wild-type (WT) C57BL/6 strain produce high levels of
TNF and generate potent inflammatory and immune responses,
whereas the susceptible BALB/c strain produces little TNF, as-
sociated with weak inflammatory and immune responses. Sec-
ond, the ECTV-encoded viral TNFR (vTNFR) homolog, termed
cytokine response modifier D (CrmD), modulates the host cy-
tokine response (22). Infection of BALB/c mice with a CrmD
deletion mutant virus (ECTVΔCrmD) augmented inflammation,
natural killer (NK) cell, and cytotoxic T lymphocyte (CTL) ac-
tivities, resulting in effective control of virus replication and
survival.
Significance
Excessive tumor necrosis factor (TNF) production during some
respiratory viral infections is associated with lung pathology
and death. We show here that deficiency in TNF also causes
significant pathology during respiratory poxvirus infection of
mice but has no effect on viral load. TNF deficiency causes in-
creased production of interleukin (IL)-6, IL-10, transforming
growth factor beta, and interferon gamma and overactivation
of STAT3 signaling. Cytokine blockade, or STAT3 inactivation,
ameliorates lung pathology in TNF-deficient mice. The mem-
brane form of TNF alone is necessary and sufficient for regu-
lating inflammation and the prevention of lung pathology.
Targeting specific cytokines or cytokine signaling pathways to
can ameliorate lung inflammation during respiratory viral in-
fections but the timing and duration of the interventive mea-
sures are critical.
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Excessive TNF production, via NF-κB activation, can induce
the production of other proinflammatory cytokines, including
interleukin 6 (IL-6), which in turn can activate signal transducer
and activator of transcription 3 (STAT3) (23). Both NF-κB and
STAT3 signaling pathways are closely intertwined and regulate
an overlapping group of target genes including those associated
with inflammation (24, 25). STAT3 activation forms phosphor-
ylated STAT3 (pSTAT3), whose activity is regulated through
dephosphorylation by phosphatases (26, 27) or by pSTAT3 in-
hibitors, namely protein inhibitor of activated STAT3 (PIAS3)
(28–30) and suppressor of cytokine signaling 3 (SOCS3) (31).
Using the mousepox model, we have found that TNF has no
antiviral effects in C57BL/6 mice but plays a key role in regu-
lating inflammatory cytokine production and resolution of lung
inflammation during a respiratory infection. C57BL/6 WT mice
and those expressing only the noncleavable transmembrane form of
TNF (mTNFΔ/Δ) recovered from ECTV infection, whereas TNF-
deficient (TNF−/−) mice succumbed with uniform mortality. TNF
deficiency dysregulated IL-6, IL-10, transforming growth factor
beta (TGF-β), and interferon gamma (IFN-γ) production accom-
panied by significant lung pathology in virus-infected mice. Cyto-
kine blockade with monoclonal antibodies (mAb) against each of
these cytokines significantly reduced lung pathology contempora-
neous with increased levels of PIAS3 and/or SOCS3 expression,
suggesting that excessive cytokine production in TNF−/− mice might
be due to dysregulated STAT3 activation. Indeed, short-term
treatment of ECTV-infected TNF−/− mice with cytokine mAb or
STAT3 inhibitor significantly reduced lung pathology. However,
only long-term treatment with anti–IL-6 or anti–TGF-β resulted in
the recovery of mice and effective virus control. During respiratory
ECTV infection, TNF deficiency results in dysregulated cytokine
production, in part due to overactivation of STAT3 signaling,
causing massive lung pathology and death.
Results
mTNF Is Induced Rapidly in WT Mice and TNF Deficiency Exacerbates
Respiratory ECTV Infection Independent of Viral Load or
Cell-Mediated Immunity. In WT mice infected with ECTV in-
tranasally (i.n.), TNF messenger RNA (mRNA) was detectable
in lungs at day 3 postinfection (p.i.), with levels still relatively
high at day 12 (SI Appendix, Fig. S1A). In lung homogenates,
sTNF was detectable from about day 7 p.i. (SI Appendix, Fig.
S1B), whereas mTNF was detectable earlier, but levels of both
forms were highest at day 12 p.i. (SI Appendix, Fig. S1C).
WT, TNF−/−, and mTNFΔ/Δ mice infected with ECTV i.n.
were assessed for clinical scores, weight loss, survival, viral load,
NK cell, and virus-specific CTL responses.
Evaluation of the clinical presentation using a scoring system
(SI Appendix, Table S1) indicated that TNF−/− animals fared
significantly worse than WT or mTNFΔ/Δ mice beginning at day 8
p.i. (Fig. 1A). Mild signs of infection were evident in all three
strains beginning at days 5 and 6 p.i., but only TNF−/− mice
showed postural changes and inactivity from day 7. All three
strains exhibited piloerection, lacrimation, and nasal discharge
from day 8 p.i., but only TNF−/− mice succumbed to infection.
All strains lost weight from day 7 p.i.; however, WT and
mTNFΔ/Δ animals started to recover from day 12 p.i. (Fig. 1B).
One mTNFΔ/Δ mouse died at day 9, whereas all TNF−/− mice
succumbed between days 9 and 11 p.i. (Fig. 1C).
Susceptibility to ECTV infection is generally associated with
uncontrolled virus replication (21, 32). However, susceptibility of
TNF−/− mice to ECTV was not due to increased viral load in
lungs, liver, or spleen (Fig. 1 D–F). Conversely, mice deficient in
IFN-α/β receptor or IFN-γ, strains known to rapidly succumb to
mousepox due to uncontrolled virus replication (33), had sig-
nificantly higher viral load in lungs compared to WT or TNF−/−
mice (Fig. 1G). ECTV-encoded CrmD had no effect on virus
replication as ECTVΔCrmD (22) replicated to levels comparable
to WT virus (ECTVWT; Fig. 1H).
Since early activation of NK cells and CTL responses are
critical for virus control (21, 34–36), we investigated the effect of
TNF deficiency on these responses. NK cell responses in the
lungs (SI Appendix, Fig. S2 A and B) and spleens (SI Appendix,
Fig. S2 C and D) were similar at days 5 and 7 p.i. in WT,
mTNFΔ/Δ, and TNF−/− strains. Likewise, TNF deficiency did not
affect the antiviral CTL responses in the lungs (SI Appendix, Fig.
S2E) or spleen (SI Appendix, Fig. S2F) at day 9 p.i. Thus, TNF
neither possesses antiviral activity nor influences NK cell or CTL
responses in ECTV-infected C57BL/6 mice.
To exclude the possibility that the increased susceptibility of
TNF−/− mice was related to dysregulated organogenesis and
spatial organization of lymphoid tissue known to occur during
development (2, 4, 37), we used anti-TNF mAb to treat ECTV-
infected WT mice. Compared to the control mAb-treated ani-
mals, mice treated with anti-TNF mAb exhibited significantly
higher clinical scores (SI Appendix, Fig. S3A). For ethical rea-
sons, 50% of the animals were killed at day 8 and considered
dead the following day (SI Appendix, Fig. S3B). The remaining
animals were killed on day 9 to assess lung histopathological
changes in sections (SI Appendix, Fig. S3C) using a scoring sys-
tem (SI Appendix, Table S2) and lung tissue from all animals was
used for histopathlogical analysis and to measure viral load. The
histopathological scores were higher in anti-TNF mAb-treated
animals but there were no differences in viral load between the
groups (SI Appendix, Fig. S3D). These results further confirmed
that TNF is critical for recovery of mice from ECTV infection
but that the cytokine has no antiviral effects.
Exacerbation of Lung Pathology in the Absence of TNF. There were
minimal changes in lung histological sections of WT and
mTNFΔ/Δ mice on days 3, 5, and 7 p.i., whereas edema was
visible at day 7 in TNF−/− animals (SI Appendix, Fig. S4A).
By day 9 p.i., edema and leukocyte extravasation were seen
histologically in all strains. Resolution of lung pathology was
evident in WT and mTNFΔ/Δ mice by day 11, but pathology
worsened in TNF−/− mice. As the clinical, virological, immuno-
logical, and histological responses to ECTV infection were
similar in WT and mTNFΔ/Δ mice, we undertook further analysis
of the response to ECTV infection in WT and TNF−/− mice.
Infected TNF−/− lungs were more congested, boggier, physi-
cally larger, and contained more and bigger necrotic lesions
compared to WT lungs (Fig. 2A). TNF−/− lungs also had signif-
icantly higher levels of fluid in lung interstitial spaces on days 7,
9, and 11 p.i. (Fig. 2B) and protein in bronchoalveolar lavage
fluid (BALF) compared to the WT lungs (Fig. 2C).
Detailed microscopic examination of lung sections (Fig. 2 D
and E) revealed that lung pathology was more severe in virus-
infected TNF−/− mice. Both strains had intraalveolar and peri-
vascular edema, but in the TNF−/− group the fluid extravasation
on almost the entire lobe led to alveolar wall collapse by day 9.
Resolution of pathology was evident in WT lungs by day 11,
whereas in TNF−/− lungs alveolar wall damage and intraalveolar
and parenchymal edema continued to increase from day 9 to day
11 p.i., and the bronchial epithelia were completely denuded.
TNF−/− lungs had significantly higher histopathological scores
than WT lungs on days 9 and 11 p.i. (Fig. 2F). In WT mice, the
histological scores were lower at day 11 compared to day 9,
consistent with recovery. The data suggested that TNF plays an
important role in antiinflammatory processes.
TNF Is Produced by Many Cell Types and Its Deficiency Does Not
Affect Leukocyte Recruitment to the Lungs or Regulatory T Cell
Function but Results in Dysregulated Inflammatory Cytokine
Production. Cell types responsible for TNF production within
the infected lungs were identified by immunohistochemistry




























(Fig. 3 A and B), and these were observed in the bronchial ep-
ithelium and alveoli where the virus antigen was also present (SI
Appendix, Fig. S4B). Morphologically identified leukocyte sub-
sets were present in both mouse strains but TNF protein was not
detected in TNF−/− lungs (Fig. 3B). In WT mice, TNF protein
was produced by bronchial epithelial cells and by multiple leu-
kocyte subsets (Fig. 3A). Flow cytometric analysis of digested
lungs indicated that the total number of leukocytes (CD45+; SI
Appendix, Fig. S5A) or individual leukocyte subsets (Fig. 3C)
were similar in both mouse strains. Histological analysis of
TNF−/− lungs suggested that there was a confluence of leuko-
cytes in specific areas at day 11 p.i. (Fig. 2E), but the total
number of leukocytes within the lungs had decreased compared
to day 9 p.i. (SI Appendix, Fig. S5 A–C). The consolidation of
leukocytes in infected TNF−/− mice was therefore not related to
an increase in their numbers but may have been due to changes
in the activation status of leukocyte subsets. As TNF signaling via
TNFR2 promotes the expansion and function of murine
CD4+CD25+ regulatory T cells (Tregs), TNF deficiency may
have impacted Treg function (38–40). However, CD25+ cell
depletion with an anti-CD25 mAb had no effect on clinical
scores, weight loss, or viral load in both strains (SI Appendix, Fig.
S5 D–F), suggesting that Treg function was not affected by TNF
deficiency.
Fig. 1. TNF is critical for recovery of mice from ECTV infection but is not required for control of virus replication. Groups of WT, TNF−/−, and mTNFΔ/Δ mice
were infected i.n. with ECTV. (A) Clinical scores, (B) weights, and (C) survival during the course of infection. Mice were killed (n = 5) on the indicated days p.i.
Viral load in (D) lungs, (E) livers, and (F) spleens. (G) Lung viral load in ECTV-infected WT, TNF−/−, IFN-α/βR−/−, and IFN-γ−/− mice (day 5 p.i.). (H) Lung viral load
in five WT and five TNF−/− mice infected with ECTVWT or ECTVΔCrmD (day 7 p.i.). Data are expressed as means ± SEM. Two-tailed Mann–Whitney U test for A,
multiple unpaired t tests with Holm–Sidak’s correction for multiple comparisons for B, log-rank test for C; log-transformed viral loads analyzed by two-way
ANOVA with Holm–Sidak’s correction for multiple comparison for D–H, and broken lines correspond to the limit of detection in plaque assays. **P < 0.01;
****P < 0.001.




































We next measured levels of some specific cytokines in un-
infected and virus-infected lung tissue. TNF protein was not
detected in TNF−/− animals, whereas it was detectable in WT
mice at day 9 p.i., and levels increased substantially by day 12 p.i.
(Fig. 3D), consistent with mRNA levels (SI Appendix, Fig. S5G).
Strikingly, both protein (Fig. 3 E–H) and mRNA (SI Appendix,
Fig. S5 H–K) levels of IFN-γ, IL-6, IL-10, and TGF-β were sig-
nificantly higher in lungs of TNF−/− mice compared to WT an-
imals at day 12 p.i.
Blockade of Specific Cytokine Function Dampens Lung Pathology. To
ascertain whether the increased production of cytokines identi-
fied in Fig. 3 E–H contributed to lung pathology, we used mAb
against IFN-γ, IL-6, IL-10R, or TGF-β to block cytokine function
at day 7 p.i., coincident with histological evidence of pulmonary
edema (SI Appendix, Fig. S4A), and killed mice at day 9.
Treatment with control mAb (rat immunoglobulin G [IgG])
had minimal impact on disease outcome and, as expected, the
lung pathology in WT mice (Fig. 4 A and B) was not as severe as
Fig. 2. TNF deficiency in mice during ECTV infection exacerbates lung pathology. Five naïve or infected mice were killed on days 7, 9, and 11 p.i. (A) Gross
morphology of lungs from naïve WT and TNF−/− mice in comparison to lungs from day 11 p.i. Arrows point to necrosis on the lung surface. (B) Lung wet-to-dry
weight ratios as measure of lung fluid extravasation and (C) protein concentration in BALF at days 0 and 11 p.i. Histological changes in naïve and ECTV-
infected (D) WT and (E) TNF−/− mice at days 9 and 11 p.i. Slides were examined at 400× magnification. (Scale bars, 100 μm.) Parenchymal and perivascular
edema (thick arrows), and bronchial epithelial necrosis (thin arrows) are shown. (F) Lung histopathological scores on days 0, 9, and 11 p.i. using a scoring
system (SI Appendix, Table S2). Data are expressed as means ± SEM. For B, C, and F, statistical analyses were undertaken as for Fig. 1 D–H. *P < 0.05; **P < 0.01;
***P < 0.0001.




























in TNF−/− mice (Fig. 4 K and L). Blockade of IFN-γ, IL-6, IL-10, or
TGF-β function reduced lung pathology, including the amelioration
of edema and bronchial epithelial damage in WT (Fig. 4 C–J) and
TNF−/− (Fig. 4 M–T) mice. The histopathological scores in anti-
cytokine mAb-treated WT lungs were not significantly different
from the control mAb-treated group (Fig. 4U), possibly because
WTmice did not produce high levels of these cytokines (Fig. 3) and
the lung pathology was not as severe as in the TNF−/− mice. With
the exception of anti–IL-6 treatment, cytokine blockade did not
affect viral load in WT mice (Fig. 4V).
In contrast, in TNF−/− mice, treatment with mAb to IFN-γ,
(Fig. 4 M and N), IL-6 (Fig. 4 O and P), IL-10R (Fig. 4 Q and R),
Fig. 3. TNF deficiency does not affect lung leukocyte recruitment but results in increased production of specific inflammatory and regulatory cytokines. Immuno-
histochemistry of lung sections for TNF expression by bronchial epithelial cells and leukocyte subsets in ECTV-infected (A) WT and (B) TNF−/− mice on day 9 p.i. Slides
were examined at 1,000× magnification. Arrows point to bronchial epithelial cells and different cell types in the alveoli. (Scale bars, 50 μm.) Cells were identified by
morphology and the same panels have been used to indicate the presence of neutrophils and monocytes in a lung section from TNF−/− mice. (C) Flow cytometry
analysis of digested lungs from naïve and ECTV-infected WT and TNF−/− mice at day 9 p.i. Leukocyte subsets were identified by CD45.2 expression and one or more
specific phenotypic markers. Concentrations of (D) TNF, (E) IFN-γ, (F) IL-6, and (G) IL-10 in lung homogenates determined by cytokine bead array. (H) TGF-β con-
centrations measured by ELISA. For C–H, data are expressed as means ± SEM and analyzed as described for Fig. 1 D–H. *P < 0.05; ***P < 0.001; ****P <0.0001.




































or TGF-β (Fig. 4 S and T) significantly reduced histopathological
scores (Fig. 4W). The improved lung pathology in anticytokine
mAb-treated mice was not associated with a reduction in viral
titers (Fig. 4X). Curiously, viral load in TNF−/− mice in this ex-
periment was lower than in the corresponding WT groups, in-
dicating further that the worsened lung pathology in mutant mice
was not related to the viral load.
In Vivo Neutralization of Cytokine Function Increases pSTAT3, PIAS3,
and SOCS3 Levels in the Lungs of Infected Mice.Neutralization of the
function of four different cytokines led to the convergent result of
dampening lung pathology (Fig. 4), raising the possibility that their
activities may regulate a common cytokine-signaling pathway. In-
deed, phosphorylation of STAT3 may be induced by cytokines like
IL-6 (23), TGF-β (41, 42), IL-10 (43), and IFN-γ (44) and cytokine
blockade might have reduced STAT3 signaling by decreasing
pSTAT3 levels or through the induction of PIAS3 or SOCS3.
Western blot analysis revealed that levels of the inactive form
of STAT3 were similar in uninfected or infected mice regardless
of mouse strain or mAb treatment (Fig. 5A). Minimal levels of
pSTAT3 were detected in uninfected animals, and they in-
creased by about twofold in WT mice and about fivefold in
TNF−/− mice following infection (Fig. 5 A and B). In WT mice,
pSTAT3 levels increased further by about twofold with anti–IL-6
or anti–TGF-β treatment and higher than threefold following
treatment with anti–IFN-γ or anti–IL-10R (Fig. 5 A and B). In
TNF−/− mice, the increases in pSTAT3 levels above control IgG-
treated groups were marginal. There were minimal changes in
the STAT3/pSTAT3 ratios in ECTV-infected WT mice com-
pared to naïve animals but ratios were reduced in anticytokine
mAb-treated mice (Fig. 5C). In contrast, naïve TNF−/− mice had
the highest STAT3/pSTAT3 ratios, which were reduced by about
threefold following infection and another twofold in anticytokine
Fig. 4. Blockade of TNF, IFN-γ, IL-6, IL-10R, or TGF-β with mAb dampens lung pathology. Groups of WT (A–J) and TNF−/− (K–T) ECTV-infected mice were
treated on day 7 p.i. with isotype control rat IgG mAb (A, B, K, and L), or specific mAb against IFN-γ (C, D,M, and N), IL-6 (E, F, O, and P), IL-10R (G, H, Q, and R),
or TGF-β (I, J, S, and T) at 500 μg intraperitoneally (i.p.) and killed on day 9 p.i. H&E-stained lung sections were examined at 400× magnification. Perivascular
edema (thick arrows) and bronchial epithelia (thin arrows) are shown. (Scale bars, 100 μm.) In separate experiments, WT (U and V) and TNF−/− (W and X) mice
were infected with ECTV and treated with mAb as above. Histopathological scores and viral load in WT mice (U and V) and TNF−/− mice (W and X) at day 9 p.i.
Data are expressed as means ± SEM and analyzed using unpaired t test for U and W. For V and X, data were analyzed as described for Fig. 1 D–H. *P < 0.05.




























mAb-treated mice with the exception of animals treated with
anti–TGF-β.
The basal levels of PIAS3 were about threefold lower in
TNF−/− mice compared with WT animals (Fig. 5 A and D). In-
fection augmented PIAS3 levels in both strains, with further
increases noted after blockade of cytokine function. In TNF−/−
mice, the PIAS3 band density increased by the largest magnitude
following blockade of IL-6, IL-10R, and TGF-β. The increase in
PIAS3 levels may have contributed to dampening of pSTAT3
activity and, as a consequence, reduction in lung pathology.
Naïve animals did not express SOCS3, and this protein was
detectable at only low levels after infection of both WT and
TNF−/− mice (Fig. 5 A and E). Treatment with mAb against IL-6
but not the other cytokines resulted in significant increases in
levels of SOCS3.
Inhibition of STAT3 Activation Ameliorates Lung Pathology. The
preceding data suggested that it might be possible to dampen
lung pathology through inhibition of STAT3 activation. Treat-
ment with S3I-201, a selective STAT3 inhibitor that blocks
STAT3 phosphorylation and dimerization (28), 7 d after ECTV
infection resulted in a significant reduction in clinical scores in
WT (Fig. 6A) and TNF−/− (Fig. 6B) mice and lung histopatho-
logical scores in both strains at day 9 p.i. (Fig. 6C). However, the
treatment did not have any effect on viral load in either strain
(Fig. 6D). Microscopically, STAT3 inhibitor treatment improved
lung pathology in WT (Fig. 6E) and TNF−/− (Fig. 6F) lungs. These
results indicate that dysregulated inflammatory cytokine production
and generation of lung pathology in the absence of TNF function is
associated, at least in part, with hyperactivation of STAT3.
S3I-201 treatment in WT mice resulted in significant increases
in the levels of mRNA for TNF (Fig. 6G), IL-10 (Fig. 6H), TGF-
β (Fig. 6I), IFN-γ (Fig. 6J), IL-1α (Fig. 6K), IL-1β (Fig. 6L), and
IL-12p40 (Fig. 6M). In sharp contrast, in TNF−/− mice, STAT3
inhibitor treatment resulted in reductions in mRNA levels for
IL-10 (Fig. 6H), IFN-γ (Fig. 6J), and IL-12p40 (Fig. 6M). Al-
though levels of mRNA for IL-1β (Fig. 6L) and IL-6 (Fig. 6N)
were also reduced compared to the mock-treated group, they
were not statistically significant. Crucially, STAT3 inhibitor
treatment reduced mRNA levels of a number of cytokines in
TNF−/− mice down to those observed in mock-treated WT ani-
mals. Thus, the effect of STAT3 inhibitor treatment on the ex-
pression of inflammatory cytokine mRNA transcripts is clearly
influenced by TNF.
Fig. 5. Short-term cytokine blockade increases levels of pSTAT3, PIAS3, and SOCS3 expression in ECTV-infected lungs. Five ECTV-infected WT and TNF−/− mice
were treated on day 7 p.i. with control rat IgG or mAb against IFN-γ (α-IFN-γ), IL-6 (α-IL-6), IL-10R (α-IL-10R), or TGF-β (α-TGF-β) at 500 μg i.p. Lungs were
collected on day 9 p.i. and homogenized and homogenates used for detection of STAT3, pSTAT3 (tyrosine-705 phosphorylation), PIAS3, and SOCS3 protein
levels (A) by Western blot analysis. The data shown are from the lungs of one mouse per treatment group and there was minimal variation between in-
dividual mice in each group. Band densities (B–E) were quantified using the Thermo Scientific Pierce MYImageAnalysis Software.




































TNF−/− Mice Recover from ECTV Infection after Extended Treatment
with Anti–IL-6 or TGF-β. Short-term treatment with anticytokine
mAb or STAT3 inhibitor significantly reduced lung pathology in
TNF−/− animals. We therefore determined whether prolonged
treatment with these agents would allow TNF−/− mice to recover
from an otherwise lethal infection. ECTV-infected TNF−/− mice
were monitored for 22 d after treatment with either a control
mAb or mAb against IL-6, IL-10R, or TGF-β beginning at day 7
p.i., and every 2 d thereafter until day 20 p.i., or with STAT3
inhibitor from day 7 p.i. and every day thereafter until day 20 p.i.
Control mAb- and anti–IL-10R-treated mice exhibited 100%
mortality by days 10 to 13 p.i., whereas animals treated with
anti–IL-6 or anti–TGF-β survived the infection (Fig. 7A). Four of
five animals treated with the STAT3 inhibitor died between days
11 and 18, and one animal survived until the day it was killed.
Extended treatment with anti–IL-10R did not improve weight
loss whereas all animals treated with anti–IL-6 or anti–TGF-β
showed improvements in body weights from day 13 (Fig. 7B) and
clinical scores (Fig. 7C) within 1 to 2 d after initiation of treat-
ment. The one STAT3 inhibitor-treated mouse that survived
gained weight from day 19 p.i. (Fig. 7B) in parallel with a reduction
in clinical scores (Fig. 7C). Viral load in lungs of all control mAb- or
anti–IL-10R-treated mice or the 4 STAT3 inhibitor-treated mice
that died was high and between 6.5 and 8.5 log10 plaque-forming
units per gram of lung tissue, whereas they were either at or below
the limit of detection in mice treated with anti–IL-6, anti–TGF-β,
or STAT3 inhibitor and killed on day 22 p.i. (Fig. 7D).
Histologically, only prolonged treatment with anti–IL-6 reduced
lung pathology (Fig. 7E). All control mAb-, anti–TGF-β- or anti–IL-
10R-treated mice and four of five STAT3 inhibitor-treated mice had
significant lung pathology. The finding with anti–TGF-β treatment
was surprising as even with this level of pathology the viral load was
close to the limit of detection, the clinical scores were close to
baseline, and the animals regained their loss in body weights.
The results indicate that the immune dysregulation and pul-
monary pathology in TNF−/− mice following infection with
ECTV were due to excessive production of some inflammatory
and regulatory cytokines.
Discussion
TNF plays fundamental roles in homeostasis, acute inflammation,
and antimicrobial defense but excessive or chronic production of
Fig. 6. STAT3 inhibition dampens lung inflammation in ECTV-infectedmice. Five ECTV-infectedWT and TNF−/−mice were treated on days 7 and 8 p.i. with 5 mg/kg
of the STAT3 inhibitor S3I-201, andmock-treated groups were given inhibitor diluent. Clinical scores of (A) WT and (B) TNF−/−mice. (C) Lung histopathological scores
and (D) viral load at day 9 p.i. (E and F) Representative lung sections at 400× magnification. (Scale bars, 100 μm.) Levels of expression of mRNA transcripts for (G)
TNF, (H) IL-10, (I) TGF-β, (J) IFN-γ, (K) IL-1α, (L) IL-1β, (M) IL-12p40, and (N) IL-6. Data are expressed as means ± SEM and analyzed using Mann–Whitney U tests for
A–C. For D data were analyzed as described for Fig. 1 D–H. For G–N, data were analyzed as for Fig. 2B. *P < 0.05; **P < 0.01; ***P < 0.001.




























the cytokine can cause serious pathology and mortality. Paradoxi-
cally, our results have shown that TNF deficiency in mice also re-
sults in significant pathology and death during mousepox, a
surrogate model for smallpox. The two forms of TNF, sTNF and
mTNF, can mediate effector functions, but the relative contribution
of each during viral infection has been unclear. In the present study,
we have established that mTNF alone is necessary and sufficient to
protect against lung pathology in ECTV-infected mice. A number
of studies have previously shown that mTNF alone is sufficient to
protect against intracellular protozoan parasites and bacteria
(45–48). Our results indicated that neither sTNF nor mTNF is
necessary to control ECTV replication but that mTNF was suffi-
cient to regulate lung pathology during respiratory infection.
The immunopathology was not due to excessive leukocyte
infiltration into the lungs as numbers and phenotypes of leuko-
cytes present in virus-infected WT and TNF−/− groups were not
different. However, TNF deficiency likely contributed to dysre-
gulated leukocyte activation and cytokine production that
resulted in immunopathology. TNF deficiency did not affect the
numbers or effector functions of NK cells, CTL, or CD4+ Treg
cells. Both NK cell and CD8+ T cell-mediated CTL responses
are essential for early virus control and recovery of mice from
ECTV infection (21, 34–36, 49). The absence of any impact of
TNF deficiency on NK cell and CTL responses is also consistent
with a lack of any effect on viral load.
In humans, treatment with TNF blocking agents can exacer-
bate some viral infections (50, 51) but not others like influenza A
virus (IAV) (52). In mice, TNF deficiency did not have any ef-
fects on IAV titers but exacerbated illness and heightened lung
immunopathology (16, 53). Our results with the ECTV model
are consistent with findings in the IAV model. However, one key
difference between the two viral models is that TNF deficiency
did not affect leukocyte recruitment to lungs in ECTV-infected
animals, whereas it increased inflammatory cell infiltration in
IAV-infected mice. The current study also indicates that TNF,
unlike IFN-α/β and IFN-γ (21, 32, 33), has no antiviral activity
against ECTV in C57BL/6 mice but is necessary to regulate
inflammation
WT C57BL/6 mice produced high levels of TNF during the
resolution stage (day 12 p.i.) of ECTV infection. In the absence
of TNF, levels of IFN-γ, IL-6, IL-10, and TGF-β were signifi-
cantly higher than in WT mice. Both IL-6 and IFN-γ are con-
sidered proinflammatory cytokines with the capacity to cause
tissue damage (54, 55), while TGF-β and IL-10 can regulate the
immune response but can also be proinflammatory (56). IL-10
can limit inflammation to prevent tissue damage, but a high level
Fig. 7. Long-term treatment with anti–IL-6 or anti–TGF-β protects TNF−/− mice from lethal disease. Five ECTV-infected TNF−/− mice were treated every day
from days 7 to 21 p.i. with 5 mg/kg STAT3 inhibitor and other groups were treated with control rat IgG mAb, anti–IL-6, anti–IL-10R, or anti–TGF-β at 500 μg i.p.
every 2 d from day 7 until day 21 p.i. and monitored until day 22. (A) Survival, (B) weights, and (C) clinical scores during the course of infection. (D) Lung viral
load and (E) histopathological scores of H&E sections for lungs collected from animals that were moribund and killed for ethical reasons or found dead
before day 22 p.i. and those that were killed on day 22. Data are expressed as means ± SEM. For A–C, data for STAT3 inhibitor- or anticytokine mAb-treated
mice were compared with control mAb-treated mice for each day. Survival curves (A) were compared as for Fig. 1C. Weights (B) were compared as for Fig. 1B.
Clinical scores (C) were compared as for Fig. 1A. Viral load (D) data were analyzed as described for Fig. 1 D–H. *P < 0.05; **P < 0.01; ***P < 0.001.




































of the cytokine can itself cause chronic inflammation and im-
munopathology (57). The short-term cytokine neutralization
experiments provided direct evidence that the exaggerated lung
tissue destruction in the absence of TNF was due to dysregulated
production of IFN-γ, IL-6, IL-10, and TGF-β. The timing of
cytokine neutralization in vivo, that is, coincident with genera-
tion of lung pathology, was crucial as some of these cytokines
also play very important protective roles during the early stages
of the infection, particularly, IFN-γ and IL-6 for ECTV control
very early (21, 32, 58, 59). TNF thus plays a critical role in the
suppression of immunopathology at the resolution stage of in-
fection through regulation of inflammatory/regulatory cytokine
production.
The finding that dampening of IFN-γ, IL-6, IL-10, or TGF-β
reduced lung pathology suggested at least two, nonmutually ex-
clusive, possibilities. First, IFN-γ, IL-6, IL-10, and TGF-β can
phosphorylate and activate STAT3 (23, 42, 43, 44), potentially
involving a common cytokine-signaling pathway. Second, the
different signaling pathways activated by each of these cytokines
can cross-regulate each other and a deficiency in any one cyto-
kine can dysregulate the other cytokine-signaling pathways. Our
results show that TNF deficiency dysregulated the NF-κB (IL-6),
TGF-β/Smad (TGF-β), JAK/STAT (IFN-γ), and STAT3 (IL-6
and IL-10) signaling pathways. STAT3 and NF-κB not only
regulate the expression of inflammatory genes in a cooperative
manner (24) but can also antagonize each other through negative
feedback regulation (60, 61). TNF activates STAT3 by induction
of IL-6 through NF-κB activation (23) but it can also inhibit IL-
6–mediated STAT3 activation through the recruitment of
SOCS3 (62). Furthermore, TNF-induced NF-κB activation can
inhibit TGF-β–induced Smad signaling complexes, and con-
versely TGF-β/Smad signaling can antagonize the activation of
target genes of proinflammatory stimuli of NF-κB (63, 64).
In our study, the antiinflammatory role of TNF during ECTV
infection was evidenced by low levels of PIAS3 in the lungs of
TNF−/− mice compared to the WT animals. PIAS3 not only
negatively regulates STAT3 but may also physically interact with
the p65 subunit of NF-κB, thereby inhibiting the latter’s activity
(65). PIAS3 is a small ubiquitin-like modifier E3 ligase from a
family of STAT signaling regulators and the main cellular in-
hibitor of STAT3 (28). PIAS3 expression levels are directly
correlated with inhibition of STAT3 DNA-binding and tran-
scriptional activity (66). Hence, the increased levels of pSTAT3
in the anticytokine mAb-treated mice were likely inhibited by the
correspondingly increased levels of PIAS3. IL-6 blockade also
induced high levels of SOCS3 and the combined actions of
PIAS3 and SOCS3 in this group of animals likely contributed to
effective control of lung pathology and viral load.
Dysregulated or prolonged activation of STAT3 can lead to
severe pathologic outcomes and disease (67). Our data indicate
that overactivation of the STAT3 signaling pathway, at least in
part, contributed to the exacerbated immunopathology in TNF-
deficient mice and that lung pathology could be ameliorated by
short-term inhibition of STAT3 activation. Long-term inhibitor
treatment was ineffective in reducing lung pathology or over-
coming morbidity and mortality. Such an outcome is likely due to
the possibility that some cytokines or factors produced through
the STAT3 signaling pathway may be essential for down-
regulating inflammation or involved in lung tissue repair dur-
ing the resolution phase of the infection. For instance, TGF-β is
critical for tissue repair and although long-term treatment of
TNF−/− mice with anti–TGF-β protected ECTV-infected mice
from death, the lung pathology was not resolved fully at day 22
p.i. Additionally, prolonged anti–IL-10 treatment, unlike short-
term treatment, was not protective as this cytokine is also im-
portant for regulation of the inflammatory response. Both IL-10
and TGF-β were down-regulated by STAT3 inhibitor treatment
in TNF−/− mice. It is likely that the STAT3 inhibitor mediated its
activity on multiple cell types as it has been shown to suppress
IL-6 production by bone marrow-derived macrophages and IL-
10 production by NK cells and reverse IL-6–driven reduction in
Treg-mediated suppression of T cells (68–70).
The outbred human population exhibited varying degrees of
susceptibility to smallpox (71) and, similarly, inbred strains of
mice are either resistant or susceptible to mousepox. ECTV-
resistant C57BL/6 mice generate a strong inflammatory re-
sponse and produce high levels of IL-2, IFN-γ, and TNF very
early in infection (21). In these animals, a polarized type I cy-
tokine response is not only closely associated with induction of
robust cell-mediated immunity but also generation of potent
antibody responses, both of which are critical for recovery from
infection (49, 72). In contrast, ECTV-susceptible BALB/c mice
produce significantly lower levels of these cytokines, associated
with very weak inflammatory responses and cell-mediated im-
munity (21). We have found that TNF deficiency in ECTV-
resistant mice results in significant lung pathology and death
during respiratory ECTV infection. The increased susceptibility
of mice was clearly not due to an increase in viral load. These
results might appear to contradict a recent report that TNF plays
an important antiviral role in the recovery of BALB/c mice
wherein ECTVΔCrmD infection of the BALB/c strain augmented
inflammation and cell-mediated immunity, resulting in effective
virus control and complete recovery from an otherwise lethal
infection (22). These observed differences in the outcomes of
ECTVΔCrmD infection in the two strains of mice have at least two
explanations. First, the potent immune response generated by
C57BL/6 mice can largely overcome the effects of the various
host response modifiers that ECTV encodes, including CrmD.
C57BL/6 mice produce significantly higher TNF levels than
BALB/c mice in response to ECTVWT infection (21). We predict
that in ECTVΔCrmD-infected C57BL/6 mice there would be
further increases in TNF levels. Indeed, C57BL/6 mice develop
significant lung pathology due to excessive TNF production, an
overexuberant lung inflammatory response, and succumb to
mousepox (73). Because BALB/c mice produce low levels of
TNF, CrmD likely neutralized the cytokine, resulting in weak
inflammatory and cell-mediated immune responses (22). Second,
we used the i.n. route of inoculation in our studies with C57BL/6
mice whereas Alcami and coworkers (22) used the subcutaneous
(s.c.) route. ECTV can be naturally transmitted via the s.c. as well
as i.n. routes. Both routes of virus transmission result in systemic
infection, but the i.n. route is far more sensitive, with virus repli-
cating to high titers in the lungs, and makes the resistant C57BL/6
strain succumb to mousepox at low doses of virus. Curiously, we did
not see any significant differences in the susceptibility of WT and
TNF−/− C57BL/6 mice inoculated s.c. with varying doses of ECTV.
A requirement for TNF to protect against mousepox in C57BL/6
mice, and in particular to regulate the local inflammatory response,
depends on the route of virus transmission to the host.
In summary, TNF has no direct antiviral activity against ECTV
in C57BL/6 mice but is necessary to regulate lung inflammation.
Respiratory ECTV infection of TNF−/− mice caused lethal lung
pathology due to dysregulation and excessive production of some
specific cytokines and overactivation of STAT3. Short-term
blockade of any of these cytokines with mAb or inhibition of
STAT3 activation ameliorated lung pathology in ECTV-infected
mice. Our data indicate that targeting specific cytokines or
cytokine-signaling pathways to reduce or ameliorate lung in-
flammation during a viral infection is possible but that the timing
and duration of the interventive measure will be critical.
Materials and Methods
Animal Studies. Animal experiments were performed in accordance with
protocols approved by the Australian National University Animal Ethics and
Experimentation Committee (protocol nos. A2011/011 and A2014/018). Six- to
12-wk-old female mice on a C57BL/6 background were bred under specific




























pathogen-free conditions at the Australian Phenomics Facility, Australian
National University, Canberra, Australia. Details of the genotypes of mice
used, animal experimental setup, virus inoculation, and treatment with mAb
or other drugs are found in SI Appendix, Materials and Methods.
Cell Lines and Viruses. BS-C-1 cells, MC57G, and YAC-1 were cultured in Eagle’s
minimum essential medium (EMEM) supplemented with 2 mM L-glutamine
(Sigma-Aldrich), antibiotics (penicillin, 120 μg/mL, streptomycin, 200 μg/mL, and
neomycin sulfate), 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(Hepes), and 10% fetal calf serum. This medium is referred to as complete
EMEM10. The Moscow and Naval ECTV strains were used. For more details of
the culture of cell lines and propagation and quantification of ECTV see SI
Appendix, Materials and Methods.
Lung Total Protein Concentration and Wet-to-Dry Weight Ratio. Total protein
concentration in BALF and determination of lung wet-to-dry weight ratio are
detailed in SI Appendix, Materials and Methods.
Flow Cytometric Analysis of Lung Leukocytes. Flow cytometry of lung leuko-
cytes stained with fluorochrome-conjugated mAb was undertaken as de-
tailed in SI Appendix, Materials and Methods.
Determination of Cytokine Protein Levels. The levels of IFN-γ, IL-6, IL-10, TNF,
and TGF-β in the lung homogenates were measured as detailed in SI Ap-
pendix, Materials and Methods.
Western Blot Analysis and Immunohistochemistry. Western blot analysis for
STAT3, pSTAT3, PIAS3, and SOCS3 and immunohistochemistry for detection
of TNF are detailed in SI Appendix, Materials and Methods.
Histology and Microscopic Assessment of Lung Pathology. Hematoxylin and
eosin (H&E)-stained lung sections were viewed by bright-field microscopy
(Olympus IX 71) and scored using a semiquantitative system we developed
(SI Appendix, Table S2). For more details see SI Appendix, Materials
and Methods.
RNA Extraction, Complementary DNA Generation, and qRT-PCR. Details of the
qRT-PCR including RNA extraction and complementary DNA synthesis are
found in SI Appendix, Materials and Methods.
Statistical Analysis. For details on statistical analyses see SI Appendix, Ma-
terials and Methods.
Data Availability.All data have beenmade available in the paper. Requests for
associated protocols andmaterials in the paper should be directed by email to
the corresponding author, Guna.Karupiah@utas.edu.au.
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